- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07569211
Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine (SHIM)
The goal of this pragmatic, quasi-experimental cluster trial is to evaluate whether simplified, onsite hepatitis C virus (HCV) treatment integrated into opioid agonist maintenance therapy (OAMT) clinics improves cure rates compared with referral-based care in Ukraine . The study includes adults (18 years and older) receiving OAMT with confirmed chronic HCV infection and no prior HCV treatment.
The main questions it aims to answer are:
- Does onsite Simplified HCV Integrated Management (SHIM) increase the proportion of patients achieving sustained virologic response 12 weeks after treatment completion (SVR12) compared with case management and referral (CMR) to specialist clinics?
- Does adding provider pay-for-performance (P4P) incentives to SHIM further improve progression along the HCV treatment cascade and SVR12 rates?
Researchers compared three models of care across 13 OAMT clinics in 12 Ukrainian cities:
- Case Management and Referral (CMR): structured referral to off-site specialist clinics for HCV treatment
- SHIM: simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
- SHIM + P4P: SHIM with provider incentives linked to completion of key cascade milestones All SHIM clinics were supported by Project ECHO telementoring to strengthen clinician capacity . The study used nationally procured direct-acting antivirals (DAAs) under routine program conditions and did not reimburse diagnostic costs.
Between February 2023 and December 2024, 616 eligible patients were enrolled .
Participants:
- Completed confirmatory HCV RNA testing
- Underwent simplified pretreatment clinical and laboratory assessment
- Received 12 weeks of pan-genotypic DAA treatment either onsite (SHIM arms) or at specialist clinics (CMR arm)
- Attended follow-up visits during treatment for adherence assessment and counseling
- Were prescribed HCV RNA testing 12 weeks after treatment completion to confirm cure (SVR12) The primary outcome was SVR12. Secondary outcomes included completion of pretreatment evaluation, treatment initiation, treatment completion, and completion of SVR assessment.
This study evaluates HCV care under real-world conditions during ongoing national treatment scale-up in Ukraine. The findings inform whether integrating simplified HCV treatment into OAMT clinics-and aligning provider incentives-can improve cure rates and accelerate progress toward HCV elimination in high-burden populations.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Kyiv, Ukraina, 01054
- Ukrainian Institute on Public Health Policy
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- currently receiving treatment at the selected OAT site (implying a diagnosis of opioid dependence according to ICD 10);
- aged 18 years or older;
- residing within the study catchment area; and
- having a positive HCV antibody test documented in the medical chart
Exclusion Criteria:
- previous HCV treatment history;
- active tuberculosis (assessed using 4-item screening questionnaire and confirmed according to the current national protocol);
- pregnant or planning pregnancy in the next 6 months;
- planning to move to another city in the next 6 months;
- unwillingness to undergo confirmatory HCV RNA PCR test at their own expense and treat HCV
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Case Management and Referral
structured referral to off-site specialist clinics for HCV treatment
|
structured referral to off-site specialist clinics for HCV treatment
|
|
Experimentell: Simplified HCV Integrated Management
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
|
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
|
|
Experimentell: Simplified HCV Integrated Management + Pay-for-performance
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians with provider incentives linked to completion of key cascade milestones
|
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
provider incentives linked to completion of key cascade milestones
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sustained virologic response
Tidsram: Up to 24 weeks after treatment completion
|
Number of participants who have HCV RNA below the limit of quantitation (≤50 IU/mL) based on clinical records
|
Up to 24 weeks after treatment completion
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Completion of all pretreatment diagnostic assessments
Tidsram: Through study completion, an average of 2 weeks after baseline
|
Number of participants who complete all pretreatment diagnostic assessments according to the SHIM algorithm (complete blood count, basic metabolic panel (including creatinine), hepatic function panel, fibrosis assessment, and HBsAg testing) based on clinical records
|
Through study completion, an average of 2 weeks after baseline
|
|
Treatment initiation
Tidsram: Through study completion, an average of 4 weeks after baseline
|
Number of participants who are prescribed treatment for HCV infection based on clinical records
|
Through study completion, an average of 4 weeks after baseline
|
|
Treatment completion
Tidsram: Through study completion, an average of 14 weeks after baseline
|
Number of participants who complete the full course of HCV treatment as prescribed based on clinical records
|
Through study completion, an average of 14 weeks after baseline
|
|
SVR assessment completion
Tidsram: Up to 24 weeks after treatment completion
|
Number of participants who complete HCV RNA testing for SVR confirmation based on clinical records
|
Up to 24 weeks after treatment completion
|
|
HCV reinfection
Tidsram: 12 months after treatment completion
|
Number of participants who receive a positive result of HCV RNA test at 12 months after treatment completion, based on clinical records
|
12 months after treatment completion
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Blodburna infektioner
- Narkotikarelaterade störningar
- Mentala störningar
- Infektioner
- RNA-virusinfektioner
- Virussjukdomar
- Matsmältningssystemets sjukdomar
- Leversjukdomar
- Hepatit, Viral, Human
- Smittsamma sjukdomar
- Substansrelaterade störningar
- Kemiskt inducerade störningar
- Flaviviridae-infektioner
- Hepatit
- Opioidrelaterade störningar
- Hepatit C
- Yrkesutövning
- Organisation och administration
- Administration
- Hälsovårdsekonomi och organisationer
- Patientvårdshantering
- Patientvårdsplanering
- Omfattande vård
- Finansiering, organiserad
- Ekonomi
- Ersättningsmekanismer
- Försäkring, Hälsa, Ersättning
- Remiss och samråd
- Fallhantering
- Reimbursement, Incentive
Andra studie-ID-nummer
- 127-2022
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- ICF
Studiedata/dokument
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .